Thomas M. Klaritch: It’s interesting. We had that conversation with HCA the other day and they estimate probably 80 — high 80s, low 90s percent of their workforce is never going to work from home. It’s just not practical. If you look at our portfolio specifically, as you asked the amount of administrative or back office space is probably 8% to 10% when we look at across the portfolio, and that seems pretty stable. We haven’t really had any — we haven’t seen a lot of move out in that area. So the demand continues to be there.
Connor Siversky: Okay, thank you.
Operator: The next question comes from Joshua Dennerlein from Bank of America. Please go ahead.
Joshua Dennerlein: Hey, guys. Just had some questions on your same-store NOI guidance range. When I look at the CCRCs, it looks like you’re tracking 14.3% year-to-date, but your full year range is 7% to 11%. Just kind of curious what you’re expecting in the back half there?
Peter A. Scott: Yes, maybe I’ll just take a second on that, Josh and talk generally about what we think the second half of the year looks like relative to the first half of the year within each one of our businesses. If you look at year-to-date total same-store growth, we’re at 5%, right. So pretty strong healthy number. It’s actually just a little bit above the high end of our guidance range, which was at 4.75% right now. So we’re off to a good start through the first six months of the year. CCRC has had a really strong first half of the year, and we hope to keep that momentum going. Into the second half of the year, outpatient medical year-to-date, we’re at 3.1%, which is right in line with the midpoint of our guidance, maybe a little bit better actually.
And I push Tom Klaritch every day on how do we get to the high end. So I think he thinks I’m a broken record on that. But we’ve had success getting to the high end of our guidance range pretty much every year that I’ve been CFO. So hopefully, more to come on that for the second half of the year this year for us, not to put too much pressure on Tom. But then in the lab space, look, we had a really good first quarter. We had a strong second quarter. There is probably a little bit of deceleration in the second half of the year. But I wanted to point out that the two biggest items that are impacting that; one is the Kodiak space that we got back this past quarter. We backfilled about half of it but we still have some space that needs to get backfilled in the second half of the year.
We don’t backfill if there could be a little bit of an impact on our overall same-store NOI. And then the second piece, just to remind everybody, you probably pay close attention to our top 20 list. Adverum has dropped out of our top 20 list. I mentioned it in my prepared remarks. There is downtime on that, the Revolution Medicines lease does not begin until January 1st of next year. So there’s some downtime in the back half of the year that will certainly have an impact on occupancy as well as same-store NOI in the second half of the year. But I wanted to really point out the two biggest items that will drive that decel in Life Sciences in the second half.
Joshua Dennerlein: That’s super helpful. Appreciate that. Maybe just on — actually, I remember at NAREIT, I think you guys mentioned a couple of tenants might have come to you looking for space and just given where your portfolio occupancy was. This is on the Life Science side. It sounds like you just didn’t have the space for them. What would get you guys to kind of restart the development pipeline?
